Search Results - "LUBENOW, N"

Heparin‐induced thrombocytopenia: a prospective study on the incidence, platelet‐activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes by GREINACHER, A., JUHL, D., STROBEL, U., WESSEL, A., LUBENOW, N., SELLENG, K., EICHLER, P., WARKENTIN, T. E.

“…Introduction: Platelet‐activating antiplatelet factor 4/heparin (anti‐PF4/heparin) antibodies are the major cause of heparin‐induced thrombocytopenia (HIT)…”
Get full text

Lepirudin in patients with heparin‐induced thrombocytopenia – results of the third prospective study (HAT‐3) and a combined analysis of HAT‐1, HAT‐2, and HAT‐3 by LUBENOW, N., EICHLER, P., LIETZ, T., GREINACHER, A.

“…Objectives: To assess efficacy and safety of lepirudin in patients with heparin‐induced thrombocytopenia (HIT) in a prospective study (HAT‐3) as well as in a…”
Get full text

Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia by GREINACHER, A, LUBENOW, N, EICHLER, P

“…Lepirudin (Refludan) is a hirudin derivative. It is a direct thrombin inhibitor obtained by recombinant technology from the medicinal leech and is approved for…”
Get full text

Predonation finger lancet punctures: a potential risk factor for interdonor pathogen transmission in the blood donor clinic by Greinacher, A., Lubenow, N.

“…Background and Objectives Point‐of‐care testing using capillary blood from a finger prick is widely used for predonation haemoglobin testing of blood donors…”
Get full text

Heparin‐induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests by GREINACHER, A., ITTERMANN, T., BAGEMÜHL, J., ALTHAUS, K., FÜRLL, B., SELLENG, S., LUBENOW, N., SCHELLONG, S., SHEPPARD, J. I., WARKENTIN, T.E.

“…Background: Laboratory confirmation of heparin‐induced thrombocytopenia (HIT) is based on detection of heparin‐dependent platelet‐activating antibodies…”
Get full text

Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients by Stattin, K., Lipcsey, M., Andersson, H., Pontén, E., Bülow Anderberg, S., Gradin, A., Larsson, A., Lubenow, N., von Seth, M., Rubertsson, S., Hultström, M., Frithiof, R.

“…The aim of this study was to investigate potential markers of coagulopathy and the effects of thromboprophylaxis with low-molecular-weight heparin (LMWH) on…”
Get full text

Motivational factors for blood donation in first‐time donors and repeat donors: a cross‐sectional study in West Pomerania by Suemnig, A., Konerding, U., Hron, G., Lubenow, N., Alpen, U., Hoffmann, W., Kohlmann, T., Greinacher, A.

“…Summary Objectives This study aimed to analyse motivational factors for blood donation in different donor groups. Background As the demographic change will…”
Get full text

Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range by Greinacher, Andreas, Eichler, Petra, Lubenow, Norbert, Kwasny, Harald, Luz, Matthias

“…This meta-analysis focuses on 2 prospective studies in patients with heparin-induced thrombocytopenia (HIT) and thromboembolic complication (TEC) who were…”
Get full text

IgG classification of anti‐PF4/heparin antibodies to identify patients with heparin‐induced thrombocytopenia during mechanical circulatory support by SCHENK, S., EL‐BANAYOSY, A., MORSHUIS, M., ARUSOGLU, L., EICHLER, P., LUBENOW, N., TENDERICH, G., KOERFER, R., GREINACHER, A., PROHASKA, W.

“…Commercial immunoassays frequently detect anti‐PF4/heparin antibodies during mechanical circulatory support (MCS), but only a small minority of patients…”
Get full text

Prophylactic platelet transfusions by Pietersz, R. N. I., Reesink, H. W., Panzer, S., Gilbertson, M. P., Borosak, M. E., Wood, E. M., Leitner, G. C., Rabitsch, W., Ay, C., Lambermont, M., Deneys, V., Sondag, D., Compernolle, V., Legrand, D., François, A., Tardivel, R., Garban, F., Sawant, R. B., Rebulla, P., Handa, M., Ohto, H., Kerkhoffs, J.-L. H., Brand, A., Zhiburt, E., Cid, J., Escolar, G., Lozano, M., Puig, L., Knutson, F., Hallböök, H., Lubenow, N., Estcourt, L., Stanworth, S., Murphy, M. F., Williams, L., Mraz, D.L., Ross, R.L., Snyder, E.

Get full text

Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin by Lubenow, N, Greinacher, A

“…Recombinant hirudins have a definite role in the treatment of patients with heparin-induced thrombocytopenia (HIT). The most important adverse effects are…”
Get full text

Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin by Lubenow, N, Greinacher, A

Get full text

Drug-induced and drug-dependent immune thrombocytopenias by Greinacher, A, Eichler, P, Lubenow, N, Kiefel, V

“…Thrombocytopenia is a frequent comorbid condition in many in hospital patients. In some patients, drugs are the cause of low platelet counts. While cytotoxic…”
Get more information

Standardizing the freeze‐thaw preparation of growth factors from platelet lysate by Strandberg, Gabriel, Sellberg, Felix, Sommar, Pehr, Ronaghi, Martin, Lubenow, Norbert, Knutson, Folke, Berglund, David

“…BACKGROUND Over the past decades, the focus on the regenerative properties of platelets (PLTs) has intensified and many PLT‐derived growth factors are readily…”
Get full text

Heparin-platelet factor (PF) 4 antibodies in patients with pseudothrombocytopenia: coincidence or association? by Schwarzinger, I, Speiser, W, Lubenow, N, Greinacher, A, Panzer, S

Get more information

Patterns of blood use in Sweden from 2008 to 2017: A nationwide cohort study by Auvinen, Marja‐Kaisa, Zhao, Jingcheng, Lassén, Ewa, Lubenow, Norbert, Seger Mollén, Agneta, Watz, Emma, Wikman, Agneta, Edgren, Gustaf

“…Background Transfusion patterns in Sweden have not been characterized on a nationwide level. Study Design and Methods We conducted a nationwide descriptive…”
Get full text

S4A-03 SESSION 4A: GENERALITIES IN CRANIOSYNOSTOSIS – PART I A TRANSFUSION REGIMEN WITH SAME-DONOR PACKED RED BLOOD CELLS REDUCES EXPOSURE TO MULTIPLE BLOOD DONORS IN CRANIOSYNOSTOSIS SURGERY by Mogensen, S., Nowinski, D., Lubenow, N., Enblad, P., Frykholm, P.

Get full text

Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies by Lubenow, Norbert, Eichler, Petra, Lietz, Theresia, Farner, Beate, Greinacher, Andreas

“…This analysis of 3 prospective multicenter trials in patients with laboratory-confirmed acute heparin-induced thrombocytopenia (HIT) without clinically evident…”
Get full text

Rational design of new CpG oligonucleotides that combine B cell activation with high IFN‐α induction in plasmacytoid dendritic cells by Hartmann, Gunther, Battiany, Julia, Poeck, Hendrik, Wagner, Moritz, Kerkmann, Miren, Lubenow, Norbert, Rothenfusser, Simon, Endres, Stefan

“…Two different types of CpG motif‐containing oligonucleotides (CpG ODN) have been described: CpG‐A with high induction of IFN‐α in plasmacytoid dendritic cells;…”
Get full text

Recombinant hirudin in clinical practice : Focus on lepirudin by GREINACHER, Andreas, LUBENOW, Norbert

“…Clinical applications for recombinant hirudins have been investigated for the past 10 years. The first indication for which a hirudin-lepirudin-has been…”
Get full text